Arcutis Biotherapeutics ARQT 深 沪
已收盘 08-01 16:00:00 美东时间
14.29
-0.290
-1.99%
华盛通- 最 高14.55
- 今 开14.37
- 成交量 167.25万股
- 最 低 14.1207
- 昨 收 14.58
- 总市值 17.01亿
- 52周最高 17.75
- 市盈率 静 --
- 换手率 1.41%
- 52周最低 8.03
- 委 比 14.16%
- 总股本 1.19亿
- 历史最高 40.88
- 量 比 1.19
- 振 幅 2.94%
- 历史最低 1.76
- 每 手 1
- 风险率 2.31%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Arcutis to Report Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) will report second quarter 2025 financial results and provide a business update on August 6, 2025. A conference call and webcast will be held at 4:30 p.m. ET the same day, and the webcast will be available on the Company’s website. Arcutis focuses on developing innovative treatments for immune-mediated dermatological diseases with a portfolio of advanced targeted topicals.
07-23 20:00
Arcutis Biotherapeutics' ZORYVE cream 0.15% received recommendation in focused guideline update for management of adult AD from AAD.
The American Academy of Dermatology (AAD) provided evidence-based recommendation for the use of ZORYVE® (roflumilast) cream 0.15% in adults with mild to moderate atopic dermatitis (AD)Recommendation reflects
06-26 20:08
Arcutis’ ZORYVE® (roflumilast) Cream 0.15% Receives Strong Recommendation in American Academy of Dermatology Updated Guidelines for Adult Atopic Dermatitis
ZORYVE® (roflumilast) cream 0.15% has received a strong recommendation from the American Academy of Dermatology for adults with mild to moderate atopic dermatitis (AD). As a next-generation, steroid-free topical PDE4 inhibitor, ZORYVE is the first FDA-approved branded treatment for AD, plaque psoriasis, and seborrheic dermatitis. It offers clinically meaningful improvements in disease severity and pruritus with favorable safety and tolerability. ...
06-26 12:00
华东医药创新皮肤外用制剂0.3%罗氟司特泡沫（ZORYVE）脂溢性皮炎III期临床试验申请获NMPA批准
转自：华东医药股份有限公司 2025年6月9日，华东医药股份有限公司（以下简称“公司”）全资子公司杭州中美华东制药有限公司（以下简称“中美华东”）收到国家药品监...
06-11 19:18
华东医药(000963.SZ)：中美华东0.3%罗氟司特泡沫临床试验申请获批
华东医药(000963.SZ)发布公告，2025 年6月9日，公司全资子公司杭州中美华东制药有限公司(“中美华东”)收到国家药品监督管理局(NMPA)核准签发的...
06-10 21:43
Arcutis Enrolls First Child in INTEGUMENT-INFANT Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis
Arcutis Biotherapeutics, Inc. has initiated a Phase 2 study, INTEGUMENT-INFANT, to assess the safety and tolerability of ZORYVE (roflumilast) cream 0.05% in infants aged 3 months to 24 months with atopic dermatitis (AD). AD affects approximately 9.6 million children in the U.S., with 60% of cases developing symptoms within the first year of life. ZORYVE, a highly potent PDE4 inhibitor, is being evaluated as a potential long-term treatment for inf...
06-10 12:00
Arcutis says Zoryve data demonstrates durable atopic dermatitis improvements
New phase 3 data released by Arcutis Biotherapeutics (NASDAQ:ARQT) on Zoryve (roflumilast) found that the cream leads to durable improvement in of atopic dermatitis symptoms over the long term. Result...
06-06 21:34
Arcutis To Present New Long-Term Results Of ZORYVE Cream at 2025 Revolutionizing Atopic Dermatitis Conference
New data from the Phase 3 INTEGUMENT-OLE long-term open label study show durable improvement in the signs and symptoms of atopic dermatitis (AD), including almost half of participants achieving no or minimal itch with
06-06 20:03
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arcutis Biotherapeutics granted 72,000 restricted stock units to nine new employees, vesting over four years, as inducement under the 2022 Plan, per Nasdaq rules. The units vest annually, contingent on continued employment. Arcutis focuses on innovative treatments for immune-mediated dermatological diseases.
06-06 20:00
Arcutis to Present New Long-Term Results of ZORYVE® (roflumilast) Cream at the 2025 Revolutionizing Atopic Dermatitis Conference
New Phase 3 data on ZORYVE cream for atopic dermatitis (AD) shows durable efficacy and safety. In children aged 2–5, twice-weekly application achieved disease control for 238 days, with significant reductions in itching and affected body surface area. ZORYVE cream (0.15% and 0.05%) demonstrated consistent safety and tolerability, making it a promising steroid-free option for long-term AD management in young children.
06-06 12:00
